title: The need to change our objective for artificial heart development: from totally implantable permanent ventricular assist devices to wearable therapeutic ventricular assist devices.
abstract: As a therapeutic VAD to be combined with drugs, apheresis, and cellular implants, it is advisable to develop a wearable VAD for less than 6 months of application. Such an example was shown by describing the therapeutic BCM Gyro centrifugal VAD.
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Nosé
authors.forename: Tadashi
authors.initials: T
authors.lastname: Motomura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Ohta
authors.forename: Junji
authors.initials: J
authors.lastname: Takaba
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Sugita
mesh_terms: D001781:Blood Component Removal; D009202:Cardiomyopathies / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D006353:Heart-Assist Devices / Q000009:adverse effects / Q000639:trends*; D006801:Humans; D033581:Stem Cell Transplantation; D016896:Treatment Outcome